Antipsychotic prescribing in older people

被引:17
|
作者
Neil, W
Curran, S
Wattis, J
机构
[1] Univ Huddersfield, Sch Human & Hlth Sci, Ageing & Mental Hlth Res Grp, Huddersfield HD1 3DK, W Yorkshire, England
[2] Lynfield Mt Hosp, Bradford Community Hlth NHS Trust, Bradford, W Yorkshire, England
[3] Fieldhead Hosp, SW Yorkshire Mental Hlth NHS Trust, Wakefield, Yorks, England
[4] St Lukes Hosp, SW Yorkshire Mental Hlth NHS Trust, Huddersfield, W Yorkshire, England
关键词
antipsychotics; psychiatry; older people; ELDERLY-PATIENTS; ATYPICAL ANTIPSYCHOTICS; PSYCHOLOGICAL SYMPTOMS; DOUBLE-BLIND; BEHAVIORAL DISTURBANCES; NURSING-HOME; LONG-TERM; RISPERIDONE; OLANZAPINE; PSYCHOSIS;
D O I
10.1093/ageing/afg061
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Antipsychotic medications have made a significant contribution to the care of the mentally ill people over the past 50 years, with good evidence that both typical and atypical agents are effective in the treatment of schizophrenia and related conditions. In addition they are widely used to good effect in other disorders including psychotic depression, dementia and delirium. Both typical and atypical agents may cause severe side-effects and, in the elderly in particular, there is an increased propensity for drug interactions. If used with care, antipsychotics are usually well tolerated, especially the atypical drugs. Although antipsychotics are effective at reducing psychotic symptoms their limitations should be recognised. They do not 'cure' the underlying illness, and the management of psychotic and behavioural symptoms must take into consideration treatment of physical illness as well as psychosocial interventions. In addition, the antipsychotic effect may take one to two weeks to be evident so doses should not be increased too rapidly. Often small doses are effective in the elderly if they are given sufficient time to work. As our understanding of the mechanisms of psychosis improves it is hoped that new drugs will be developed with novel mechanisms of action with improved efficacy and reduced side-effects. There are several drugs in development, some sharing similarities to currently available agents whilst others have novel mechanisms of actions involving glutamate and nicotinic receptors. Pharmacogenetics is also likely to be increasingly important over the next few years. As the genetic basis of many psychiatric disorders becomes more clearly established it is likely that drugs specifically designed for particular sub-groups of receptors will be developed. Finally, although the pharmacological treatment of psychotic disorders in younger people has been given considerable attention, there is a paucity of good quality research on antipsychotic drug use in older people. There is a need to redress this balance to ensure that the prescribing of antipsychotics in older people is evidence based.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 50 条
  • [41] Antipsychotic drugs in geriatric psychiatry
    Ibach, Bernd
    PSYCHOPHARMAKOTHERAPIE, 2010, 17 (02): : 62 - +
  • [42] Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia
    Declercq, Tom
    Petrovic, Mirko
    Azermai, Majda
    Vander Stichele, Robert
    De Sutter, An I. M.
    van Driel, Mieke L.
    Christiaens, Thierry
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (03):
  • [43] Antipsychotic prescribing in nursing homes
    McCleery, Jenny
    Fox, Robin
    BRITISH MEDICAL JOURNAL, 2012, 344
  • [44] Atypical antipsychotic drug use and falls among nursing home residents in Winnipeg, Canada
    Bozat-Emre, Songul
    Doupe, Malcolm
    Kozyrskyj, Anita L.
    Grymonpre, Ruby
    Mahmud, Salaheddin M.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2015, 30 (08) : 842 - 850
  • [45] Characteristics of antipsychotic medication prescribing on inpatient obstetric floors
    Kim Johnson
    Andrew Muzyk
    Marla Wald
    Archives of Women's Mental Health, 2016, 19 : 705 - 707
  • [46] Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing
    Niznik, Joshua D.
    Zhao, Xinhua
    He, Meiqi
    Aspinall, Sherrie L.
    Hanlon, Joseph T.
    Nace, David
    Thorpe, Joshua M.
    Thorpe, Carolyn T.
    ALZHEIMERS & DEMENTIA, 2020, 16 (04) : 630 - 640
  • [47] Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth
    Edelsohn, Gail A.
    Karpov, Irina
    Parthasarathy, Meghna
    Hutchison, Shari L.
    Castelnovo, Kim
    Ghuman, Jaswinder
    Schuster, James M.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (01): : 59 - 66
  • [48] Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
    Weintraub, Daniel
    Chen, Peijun
    Ignacio, Rosalinda V.
    Mamikonyan, Eugenia
    Kales, Helen C.
    ARCHIVES OF NEUROLOGY, 2011, 68 (07) : 899 - 904
  • [49] Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
    Mukundan, Anitha
    Faulkner, Guy
    Cohn, Tony
    Remington, Gary
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):
  • [50] Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis
    Ballard, Clive
    Isaacson, Stuart
    Mills, Roger
    Williams, Hilde
    Corbett, Anne
    Coate, Bruce
    Pahwa, Rajesh
    Rascol, Olivier
    Burn, David J.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2015, 16 (10) : 898.e1 - 898.e7